IONIS PHARMACEUTICALS INC·4

Mar 11, 4:19 PM ET

O'NEIL PATRICK R. 4

Research Summary

AI-generated summary

Updated

Ionis (IONS) EVP & General Counsel Patrick O'Neil Sells 10,148 Shares

What Happened

  • Patrick R. O'Neil, EVP, Chief Legal Officer & General Counsel of Ionis Pharmaceuticals (IONS), disposed of 10,148 shares on March 9, 2026. The reported weighted-average sale price was $75.25 per share, for total proceeds of approximately $763,662. The sale is reported as an open market or private sale (code S).

Key Details

  • Transaction date: March 9, 2026.
  • Quantity and price: 10,148 shares sold at a weighted-average price of $75.25; individual trade prices ranged from $74.98 to $75.51.
  • Total proceeds: ~$763,662.
  • Plan/footnotes: Sale executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025 (Footnote F1). Footnote F2 notes the weighted-average price and the range; the filer can provide a breakdown of trades/prices on request.
  • Shares owned after transaction: Not specified in the provided excerpt of the filing—check the full Form 4 for the "owned following report" figure.
  • Filing timeliness: Form filed March 11, 2026 for a March 9 transaction; this appears to be within the standard two-business-day filing window.

Context

  • The sale was made under a pre-established 10b5-1 plan, which generally indicates the transactions were pre-scheduled and may be routine rather than a contemporaneous signal about company prospects. For retail investors, purchases by insiders tend to be more informative than routine sales; consider this event in the context of overall insider activity and the company's fundamentals.